Haematological changes and metabolic alterations in SARS-CoV-2 infected patients hospitalised at an Infectious Diseases Center, Ibadan, Nigeria
DOI:
https://doi.org/10.15584/ejcem.2022.4.1Keywords:
COVID-19, laboratory tests, reference interval, repurposed drugs, therapeutic actionAbstract
Introduction and aim. Following the use of repurposing drugs to successfully manage coronavirus disease 2019 (COVID-19) patients in an Infectious Diseases Center (IDC) in Nigeria, it was imperative to assess haematological changes and metabolic alterations in these patients which may inform recommendations for future use.
Material and methods. Blood samples of admitted COVID-19 Nigerian patients during therapeutic management were analysed for haematological- (total white blood cells (WBC), lymphocyte, monocyte, neutrophil, eosinophil, basophil and neutrophil:lymphocyte ratio) and blood chemistry- parameters [total protein, total and conjugated bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), albumin, urea, creatinine, total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), PO43-, Ca2+, uric acid, Na+, K+, Cl- and HCO3- ] using autoanalysers. The percentages of patients having values below, within and above reference ranges were compared using Chi-square test while the mean values at admission were compared with mean values at discharge using Student t-test.
Results. The mean values of total protein, albumin, Na+, HCO3- , uric acid, Ca2+, WBC, platelets, lymphocytes, eosinophils and basophils were significantly increased in COVID-19 patients at discharge compared with COVID-19 patients at admission. Also, more percentages of COVID-19 patients at discharge compared with COVID-19 patients at admission had albumin, ALP, total bilirubin, HDL, Na+, K+, Cl- , HCO3- , urea, creatinine, WBC, lymphocytes, neutrophils, monocytes, eosinophils and basophils within normal reference intervals.
Conclusion. This study showed that most metabolic and haematological derangements were normalised by repurposing drugs in most of the COVID-19 patients at this IDC, thus supporting the continuous use of this therapeutic option.
Downloads
References
Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat. Metab. 2020;2(7):572-585. doi: 10.1038/s42255-020-0237-2
Vastag L, Koyuncu E, Grady SL, Shenk TE, Rabinowitz JD. Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism. PLoS Pathog. 2011;7(7):e1002124. doi: 10.1371/journal.ppat.1002124
Wu D, Shu T, Yang X, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl. Sci. Rev. 2020;7(7):1157-1168. doi: 10.1093/nsr/nwaa086
Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020;26:681-687. doi: 10.1038/s41591-020-0868-6
Murillo A, Vera-Estrella R, Barkla BJ, Méndez E, Arias C.F. Identification of host cell factors associated with astrovirus replication in Caco-2 cells. J Virol. 2015;89:10359-10370. doi: 10.1128/JVI.01225-15
Merino-Ramos T, Vázquez-Calvo Á, Casas J, Sobrino F, Saiz JC, Martín-Acebes MA. Modification of the host cell lipid metabolism induced by hypolipidemic drugs targeting the acetyl coenzyme A carboxylase impairs west Nile virus replication. Antimicrob. Agents Chemother. 2019;60:307-315. doi: 10.1128/AAC.01578-15
Coronavirus data explorer. www.https://ourworldindata.org/explorers/coronavirus-data-explorer. Accessed 10 Aug 2022.
Arinola OG, Alonge TO, Edem VF, et al. Changes in Renal Function Parameters of Newly Admitted COVID-19 Patients From One Infectious Diseases Center in Ibadan, Nigeria. Nig J Phys Scs. 2021;36(1):11-15.
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of
Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529-530.
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published correction appears in JAMA. 2021;325(11):1113]. JAMA. 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585
Lei F, Liu YM, Zhou F, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020;72(2):389-398. doi: 10.1002/hep.31301
Tan L, Wang Q, Zhang DY, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33-38. doi: 10.1038/s41392-020-0148-4
Akinwumi JA, Edem VF, Arinola OG. Cellular inflammatory indices in hospitalised Nigerian COVID-19 patients. Journal Health Science Research 2021;6(2):19-26.
Lu G, Wang J. Dynamic changes in routine blood parameters of a severe COVID-19 case. Clin Chim Acta. 2020;508:98-102.
Arinola GO, Fashina OA, OluyomiIshola OC, et al. Demographic attributes of COVID-19 patients in an infectious disease center of Nigeria. African J Clin Exp Microbiol. 2021;22(1):21-27.
Arinola OG, Onifade AA, Edem VF, Yaqub SA. Detection of anti SARS-COV 2 specific -IgG and -IgM antibodies in COVID-19 patients using rapid screening immunochromatographic cassettes. J Epidemiol Community Health. 2021;4(1):1059-1062.
Arinola OG. Immune Responses During Human Coronavirus Infection: Suggestions For Future Studies. Niger J Physiol Sci. 2020;35:20-25.
Arinola GO, Edem FV, Fashina OA, Olaniyan OA, Alonge TO. Cellular and Humoral Factors of Oxidative Burst in COVID-19 Patients with Malaria Parasiteamia. A Epidemiol Public Health. 2021;4(1):1060-1065.
Alonge O, Adeola F, Bamidele F, et al. Clinical Outcome Of Corona Virus Disease-19 Patients In An Infectious Disease Center, Olodo, Ibadan, Oyo State, Nigeria. Clin Med Insight. 2022. doi: 10.52845/CMI/2022-3-2-2
Arinola OG Edem VF. Antioxidant Vitamins are correlated with Different Aspects of Phagocytic Processes in Healthy Nigerians: Benefit as Supplements during Antimicrobial Treatment. Sud J Med Sc. 2020;15(3):223-234. doi: 10.18502/sjms.v15i3.7253
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-374. doi: 10.1038/s41577-020-0311-8
Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92:2105-2113. doi: 10.1002/jmv.25987
Legouis D, Ricksten SE, Faivre A, et al. Altered proximal tubular cell glucose metabolism during acute kidney injury is associated with mortality. Nat Metab. 2020;2:732-743. doi: 10.1038/s42255-020-0238-1
Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care 2020;44:578-585. doi: 10.2337/dc20-1857
Bobulescu IA, Dubree M, Zhang J, McLeroy P, Moe O. W. Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion. Am J Physiol Ren Physiol. 2008;294:F1315-F1322. doi: 10.1152/ajprenal.00550.2007
Wang S, Ma P, Zhang S. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102-2111. doi: 10.1007/s00125-020-05209-1
Dias SSG, Soares VC, Ferreira AC, et al. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators. PLoS Pathog. 2020;16(12):e1009127. doi: 10.1371/journal.ppat.1009127
Andrade Silva M, da Silva ARPA, do Amaral MA, Fragas MG, Câmara NOS. Metabolic Alterations in SARS-CoV-2 Infection and Its Implication in Kidney Dysfunction. Front Physiol. 2021;12:624698. doi: 10.3389/fphys.2021.624698
Fan Z, Chen L, Li J, et al. Clinical features of COVID‐19‐related liver damage. Clin Gastroenterol Hepatol. 2020;18:1561‐1566. doi: 10.1016/j.cgh.2020.04.002
D’Avila H, Maya-Monteiro CM, Bozza PT. Lipid bodies in innate immune response to bacterial and parasite infections. Int Immunopharmacol. 2008;8:1308-1315. doi: 10.1016/j.intimp.2008.01.035
Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology. 2020;72(5):1864-1872. doi: 10.1002/hep.31480
Wong RSM, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326:1358-1362. doi: 10.1136/bmj.326.7403.1358
Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. doi: 10.1186/s12967-020-02374-0
Qian JY, Wang B, Lv LL, Liu BC. Pathogenesis of Acute Kidney Injury in Coronavirus Disease 2019. Front Physiol. 2021;12:586589. doi: 10.3389/fphys.2021.586589
Lei HY, Ding YH, Nie K, et al. Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. Biomed Pharmacother. 2021;133:111064. doi: 10.1016/j.biopha.2020.111064
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
